ArticleResearch and practice in thrombosis and haemostasis2026
Platelet function abnormalities in acquired hemophilia A.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The bleeding pattern in acquired hemophilia A (AHA) differs from that of inherited hemophilia, being characterized by soft tissue and muscle hematomas, mucocutaneous bleeding, but seldom joint bleeding. Platelet function disorders are inherited or acquired. The acquired forms may appear in association with medications, medical conditions, and autoimmune disorders. Objectives: We chose to investigate platelet function in a series of patients with AHA due to autoantibodies inactivating coagulation factor (F)VIII. Methods: Platelet function disorders were assessed at AHA diagnosis in platelet-rich plasma according to the Scientific Subcommittee of the International Society on Thrombosis and Haemostasis recommendations. In addition, the δ- and α-granule platelet content-that is, adenine nucleotides (ADP and ATP), serotonin and β-thromboglobulin-were measured. CD40L and soluble P-selectin were also measured in plasma to investigate Results: In 11 cases with AHA and a median age of 67 years, FVIII coagulant activity was unmeasurable, the inhibitor titer was <20 Bethesda Units in 5 cases (45%) and higher than 20 Bethesda Units in 6 cases (55%). All patients showed reduced platelet aggregation and secretion. Furthermore, 4 cases with monoclonal gammopathy of undetermined significance had worse aggregation responses and an abnormal δ-granule platelet content, supporting a diagnosis of δ storage pool disease. Following remission the intraplatelet levels of ADP and serotonin improved. Conclusion: This study demonstrates that acquired platelet function abnormalities may be present in patients with AHA and perhaps contribute to the severity of their bleeding tendency.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.